A Partnership for Impact: Eau Thermale Avène and Breast Cancer Alliance

SECAUCUS, N.J., Oct. 1, 2025 /PRNewswire/ -- Pierre Fabre Laboratories, the world's second-largest dermo-cosmetics company is continuing to improve the quality of life of those impacted by breast cancer with its Eau Thermale Avène brand. During the month of October, they are taking their existing partnership with Breast Cancer Alliance (BCA) one step further to ensure patients receive the skincare comfort they deserve throughout their treatment journey.

For every Avène purchase on aveneusa.com in October, they will donate a Cicalfate+ Restorative Protective Cream 1.3 fl.oz to a breast cancer patient through the Breast Cancer Alliance's (BCA) hospital and patient programs. This initiative is especially impactful because cancer treatments like chemotherapy and radiation often cause intense skin, hair, and nail reactions. As Cicalfate+ Restorative Protective Cream is formulated with a unique postbiotic ingredient C+ Restore, this clinically proven barrier cream helps soothe, hydrate, and restore a damaged skin barrier, providing much-needed relief to those undergoing treatment. "Facing breast cancer is a fight where every moment matters. Our commitment is about making direct impact and providing patients with a solution that can help restore and soothe their skin. This partnership delivers comfort and care directly to those in need and we're proud to partner with BCA on this initiative." said Lisa Morris CEO and President of Pierre Fabre USA.

For nearly 30 years, BCA has driven progress in breast cancer care by funding cutting-edge research, surgical oncology fellowships, and critical screening and diagnostics. The partnership with Pierre Fabre Laboratories deepens their shared commitment to improving outcomes and quality of life for those impacted with breast cancer.

Beyond their collaboration with the BCA, Pierre Fabre Laboratories has a global commitment to breast cancer support that focuses on patient care, awareness, and research. This includes championing "Le Vie en Rose", a worldwide initiative that provides support to patients, many of whom are treated at the Avène Hydrotherapy Center in France. To amplify awareness about the crucial role of early detection, Pierre Fabre Laboratories is partnering with the Know Your Lemons Foundation. The company's global medical affairs team also conducts ongoing onco-dermatology research to develop the most effective skincare solutions for patients.

For more information, follow @aveneusa on Instagram and TikTok or visit www.aveneusa.com.

ABOUT EAU THERMALE AVÈNE
With over 275 years of expertise rooted in dermatology and hydrotherapy, Eau Thermale Avène by Pierre Fabre is a leading brand dedicated to managing sensitive skin disorders and is recommended by dermatologists worldwide. Formulated with dermatologist-grade ingredients, Avène offers a wide range of high-quality, efficacious solutions with proven results. As Pierre Fabre is dedicated to improving the quality of life for all skin types, dermatologists are involved from product concept, development, and testing, to create safe solutions for even the most sensitive skin. At the heart of every formula is Avène Thermal Spring Water, which is clinically proven to soothe, soften and calm the skin and all products are non-comedogenic.

ABOUT PIERRE FABRE LABORATORIES
Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. Its Medical Care activity covers 4 main therapeutic fields: oncology, dermatology, primary care and family health care.   

In 2024, Pierre Fabre Laboratories posted 3.1 billion euros in revenues, 70% of which came from international sales in 120 countries. Based in southwest France since its creation and manufacturing nearly 90% of its products in France, Pierre Fabre Laboratories employs 10,200 people worldwide. Its R&D budget amounted to 220 million euros in 2024, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions. 
Pierre Fabre Laboratories' majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company's other shareholders. This capital structure guarantees the company's independence, long-term vision and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world. 

Pierre Fabre Laboratories' CSR policy has been assessed by AFNOR Certification and has been awarded the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development).

For more information, visit www.pierre-fabre.com

Media Contact:
Beach House PR
[email protected]

SOURCE Avène USA